CVS vs LAB · P/E 16, rev $402.07B vs rev $174.4M
CVS Health Corp (CVS) versus Standard Biotools Inc (LAB) — a side-by-side from cached financials, not a winner call.
CVS Health Corp (CVS) is a healthcare plans company listed on US.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Latest reported CVS revenue for 2025-12-31 was $402.07B. Net income was $1.77B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
CVS currently screens at market cap $86.20B and trailing P/E 16.3. LAB currently screens at market cap $317.1M.
Not investment advice. Open the CVS and LAB stock pages for the full models.
Not investment advice.